VHIO

Radiation Oncology Group

Jordi Giralt

Radiation Oncologists
Sergi Benavente, Xavier Maldonado, Meritxell Molla, Begoña Navaltropo, Mónica Ramos, Victoria Reyes, Ramona Verges

SUMMARY

Our group is integrated within the Radiation Oncology Department of the Vall d’Hebron University Hospital and is actively involved in the multidisciplinary treatment of patients with malignant tumors. We also participate as principal investigators or research collaborators in a number of important clinical trials, translational research projects, as well as technology development programs.

More specifically in 2014, we achieved an increase in the number of patients treated with IMRT: 418 patients with IMRT, representing a 28% increase. Regarding our participation in the Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE) project, initiated in 2013, we have to-date succeeded in including 6 patients. This year has also marked the initiation of a dose escalation program using Image Guided RadioTherapy (IGRT), with fiducials, and we have since treated 21 patients. In addition, we have also started a stereotaxic extracranial RT in lung cancer program and have thus far treated 4 patients.

PUBLICATIONS

Total 13.
Impact Factor 124.132
Average I.F. 9.549

  • Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17. PubMed PMID: 24440473.
  • Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15. PubMed PMID: 25596659.
  • Detection of sentinel Lymph node in breasst cacner recurrence may change adjuvant treatment decisions in patiens with breast cáncer recurrence and previous axillary surgery. Cordoba O, Perez-Ceresuela F, Espinosa-Bravo M, Cortadellas T, Esgueva A, Rodriguez-Revuelto R, Peg V,Reyes V, Xercavins J, Rubio IT. Breast 2014, vol 23, 460-465.
  • Rubio IT, Landolfi S, Mollà M, Cortes J, Xercavins J, Klimberg VS. Excision of breast cancer followed by radiofrequency ablation of margins decreased the need for a second surgery for close or positive margins. Clinical breast cancer 2014: 14 (5): 346- 51. FI: 2,628.
  • Zapatero A, Guerrero A, Maldonado X, Alvarez A, Segundo CG, Rodríguez MA, Macias V, Olive AP, Casas F, Boladeras A, de Vidales CM, de la Torre ML, Villà S, de la Haza AP, Calvo FA. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 1.

MAIN RESEARCH PROJECTS

  • Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE)
    This is a european grant of the 7th framework programme (FP7) [HEALTH.2010.2.4.1-9; Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients. FP7-HEALTH-2010-two-stage]. Participating centers: The Netherlands Cancer Institute, Karolinska Institutet, Institut Gustave Roussy, Maastro Clinic, Vall d’Hebron University Hospital, Christie Hospital, European Society for Therapeutic Radiation & Oncology (ESTRO), Maastro innovations and RaySearch.
    This study explores dose escalation strategies using adaptive radiotherapy and metabolic and biological markers. We participate in the study of patients with head and neck tumors.
  • Radiogenomics Biorepository and Databank (RBD) PAR-11-167
    Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (UM1)
    In addition to DNA isolated from blood collected epidemiological data / records of patient outcomes related to the treatment.
    The main aim will be normal tissue toxicity data from patients and electronic data capture. A unique element of this project is the centralized storage of radiotherapy treatment plans.
  • Molecular factors relevant for cetuximab effect: integration with radiation therapy in head and neck cancer (FIS)
    The aim of this study is to identify factors associated with clinical response in advanced head and neck tumors treated with cetuximab-radiotherapy in order to better select patients with greater chance of response to this treatment.
  • Evaluation of the efficacy and effectiveness of new treatments for localized prostate cancer at low risk (FIS)
    A multicenter randomized trial in patients diagnosed with low-risk prostate cancer controlled clinical trial design. Patients will be treated with laparoscopic radical prostatectomy, robotic surgery, brachytherapy or IMRT. Main endpoints are performance parameters and quality of life.